CDx Diagnostics Development Services: Gene Therapy Immunogenicity, Biomarker Assays & IVD Regulatory Support

Companion diagnostics (CDx) play an increasingly important role in precision medicine by helping identify patients who may be appropriate for a particular therapeutic intervention.

The development of a CDx can involve multiple interconnected disciplines, including biomarker identification, assay development, analytical validation, clinical testing, therapeutic alignment, regulatory strategy and IVD commercialization.

The complexity increases further when diagnostic development is connected to gene therapy programs, where immunogenicity testing may involve neutralizing antibodies (NAb), total antibodies (TAb), anti-transgene responses and cellular immune-response essays.

For pharmaceutical, biotechnology and diagnostic companies, successful development requires the diagnostic and therapeutic programs to remain strategically aligned throughout development.

Maven Regulatory Solutions supports organizations with CDx development, gene therapy immunogenicity strategy and global IVD regulatory services from early development through commercialization.

What Is Companion Diagnostic Development?

A companion diagnostic is an IVD or diagnostic test developed for use with a specific therapeutic product to provide information that is essential for the safe and effective use of that therapy.

CDx development may support:

• Patient identification
• Patient selection
• Treatment eligibility
• Biomarker-defined populations
• Treatment response assessment
• Clinical trial enrollment
• Therapeutic decision-making
• Precision medicine strategies

The diagnostic development pathway should therefore be closely coordinated with the therapeutic development program.

Why Therapeutic and CDx Development Must Be Aligned

One of the major challenges in CDx development is managing the relationship between the therapeutic timeline and diagnostic timeline.

The development pathway can be viewed as:

Biomarker identification → Assay development → Analytical validation → Clinical trial testing → Clinical evidence → Regulatory submission → CDx approval → Lifecycle management

Changes to the therapeutic indication, patient population or clinical development strategy can affect the diagnostic requirements.

Early coordination can help companies establish:

• Biomarker strategy
• Intended use
• Assay platform
• Clinical study requirements
• Regulatory pathway
• Submission strategy
• Development timelines
• Commercialization requirements

CDx Biomarker and Assay Development

CDx programs may involve multiple analytical technologies depending on the biomarker and therapeutic mechanism.

Development capabilities can include:

1. IHC and Multiplex Immunofluorescence

Immunohistochemistry and multiplex immunofluorescence can support tissue-based biomarker assessment and patient stratification.

Applications may include:

• Protein expression
• Tissue biomarkers
• Spatial biomarker analysis
• Multiplex characterization
• Pathology-based patient selection

2. NGS and Genomics

Genomic technologies may support the identification of mutations, genomic signatures and other molecular biomarkers.

Potential platforms include:

• Next-generation sequencing
• qPCR
• ddPCR
• Genomic profiling
• Targeted sequencing
• Other molecular diagnostic technologies

3. Immunoassays

Immunoassay capabilities may support measurement of antibodies, cytokines and other biological markers.

Examples include:

• NAb assays
• TAb assays
• ELISA
• ELISpot
• Cytokine profiling
• Flow cytometry

Gene Therapy Immunogenicity Testing

Gene therapy programs introduce unique immunogenicity considerations.

For AAV-based gene therapies, pre-existing or treatment-emergent immune responses may influence development strategy and clinical interpretation.

Immunogenicity programs can include assessment of:

• Anti-capsid antibodies
• Neutralizing antibodies
• Total antibodies
• Anti-transgene antibodies
• Cellular immune responses
• ELISpot responses

Testing may be required across different development stages and populations, including preclinical models and human clinical studies.

NAb and TAb Assay Development

Neutralizing antibody assays can help evaluate whether antibodies interfere with the ability of a vector to deliver its therapeutic payload.

Total antibody assays can provide broader information regarding antibody responses to the relevant capsid or antigen.

A robust assay development program may include:

• Assay concept development
• Platform selection
• Method optimization
• Cut-point strategy
• Sensitivity assessment
• Specificity assessment
• Precision assessment
• Selectivity
• Robustness
• Validation
• Sample testing
• Data interpretation

The precise strategy should reflect the therapeutic mechanism, vector characteristics, clinical program and regulatory expectations.

Preclinical Through Clinical Development

Gene therapy immunogenicity testing can be integrated across the development lifecycle.

1. Preclinical Development

Early studies may help characterize immune responses and inform clinical development planning.

2. Clinical Development

Validated or appropriately qualified assays may be used to evaluate immunogenicity in clinical trials.

3. Regulatory Development

As programs progress, assay methodology, validation documentation and clinical data may become important components of regulatory submissions.

4. Commercialization

Post-approval assay and testing strategies may continue to support product lifecycle management and regulatory commitments.

CDx and Gene Therapy Regulatory Strategy

A CDx may require a dedicated regulatory pathway depending on its intended use, classification and relationship with the therapeutic.

Regulatory planning may include:

• Product classification
• Regulatory pathway assessment
• Pre-submission strategy
• Clinical evidence planning
• Analytical validation strategy
• Performance evaluation
• Technical documentation
• Labeling
• Regulatory submissions
• Therapeutic/CDx coordination
• Post-market requirements

Early engagement with regulatory authorities can help clarify expectations before major development decisions are finalized.

IVD Regulatory Services for CDx Programs

Global CDx programs can involve multiple regulatory frameworks.

1. United States

FDA regulatory pathways may include:

• 510(k)
• De Novo
• PMA
• PMA supplements
• Pre-submission meetings
• IDE-related interactions
• EUA, where applicable

The appropriate pathway depends on the diagnostic's characteristics, intended use and risk profile.

2. European Union

CDx products placed on the European market may need to comply with the IVDR, including applicable requirements for performance evaluation, technical documentation, clinical evidence, quality systems and conformity assessment.

3. United Kingdom

CDx developers should evaluate applicable UK regulatory requirements, including relevant MHRA processes and market-placement requirements.

4. Global Regulatory Strategy

A coordinated global strategy can help organizations avoid developing isolated regulatory plans for each market.

Instead, companies can establish a core evidence package and identify jurisdiction-specific requirements that need additional data or documentation.

Clinical Evidence for Companion Diagnostics

Clinical evidence is a critical component of CDx development.

The clinical strategy should consider:

• Intended patient population
• Biomarker prevalence
• Sample availability
• Clinical study design
• Comparator methods
• Cutoff selection
• Clinical sensitivity
• Clinical specificity
• Patient stratification
• Statistical analysis
• Concordance assessment

For therapeutics and CDx products developed together, clinical development timelines should be carefully coordinated.

IVD and CDx Quality Systems

CDx development requires appropriate quality controls throughout the product lifecycle.

Important areas include:

• Design controls
• Risk management
• Supplier management
• Method validation
• Change control
• Document control
• CAPA
• Nonconformance management
• Complaint handling
• Internal audits
• Training
• Post-market surveillance

Strong quality systems can help ensure that assay performance and regulatory documentation remain controlled as the product evolves.

Regulatory Documentation and Submission Support

A CDx submission can require extensive scientific and regulatory documentation.

Depending on the jurisdiction and pathway, documentation may include:

• Regulatory strategy documents
• Analytical validation reports
• Clinical performance reports
• Performance evaluation documentation
• Risk-management files
• Technical documentation
• Labeling
• Instructions for use
• Manufacturing information
• Quality-system documentation
• Clinical study documentation
• Regulatory response packages

Maven can help coordinate documentation across scientific, clinical, quality and regulatory teams.

FAQs

1. What is a companion diagnostic?

A companion diagnostic is a diagnostic test used with a particular therapeutic to provide information that is essential for the safe and effective use of that therapy.

2. Why is CDx development different from standard IVD development?

CDx development is closely connected to a specific therapeutic program. Changes in the drug's indication, patient population or clinical strategy can directly affect the diagnostic development and regulatory pathway.

3. What are NAb and TAb assays?

NAb assays evaluate neutralizing antibody activity, while TAb assays generally assess broader antibody responses. Both can be important components of immunogenicity programs for certain gene therapies.

4. Why is immunogenicity important for AAV gene therapy?

Immune responses against an AAV vector or therapeutic transgene can affect aspects of gene therapy development and clinical interpretation. Appropriate assay strategies can help characterize these responses.

5. Can CDx and therapeutic development be managed together?

Yes. Coordinating diagnostic and therapeutic development can help align biomarker strategy, clinical testing, regulatory interactions and commercialization timelines.

6. Does every CDx require the same regulatory pathway?

No. The regulatory pathway depends on factors including intended use, risk classification, technology, therapeutic relationship and jurisdiction.

Conclusion

Companion diagnostic development requires the integration of biomarker science, assay development, clinical evidence and regulatory strategy.

For gene therapy programs, complexity can increase further because immunogenicity testing may involve NAb, TAb, anti-transgene antibody and cellular immune-response assays across preclinical and clinical development.

A coordinated development strategy can help organizations establish the appropriate assay, generate relevant evidence and prepare for regulatory review while keeping therapeutic and diagnostic programs aligned.

From early biomarker development through analytical validation, clinical performance, regulatory submission and commercialization, Maven Regulatory Solutions provides regulatory and compliance support designed around the full CDx and IVD lifecycle.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports pharmaceutical, biotechnology and diagnostic organizations with:

• Companion Diagnostics Development
• CDx Regulatory Strategy
• IVD Regulatory Consulting
• Gene Therapy Immunogenicity Strategy
• NAb & TAb Assay Regulatory Support
• Biomarker Development Strategy
• Analytical Validation
• Clinical Performance Strategy
• FDA CDx Regulatory Support
• EU IVDR Compliance
• Technical Documentation
• Regulatory Submission Support
• Therapeutic-CDx Regulatory Alignment
• Inspection & Audit Readiness
• Global IVD Market Access
• Post-Market Regulatory Support

Maven Regulatory Solutions — Science. Compliance. Impact.